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TPPP/p25The disordered Tubulin Polymerization Promoting Protein (TPPP/p25), a prototype of neomorphic moonlighting
proteins, displays physiological and pathological functions by interacting with distinct partners. Here the role of
the disordered N- and C-termini straddling a middle ﬂexible segment in the distinct functions of TPPP/p25 was
established, and the binding motives responsible for its heteroassociations with tubulin and α-synuclein, its
physiological and pathological interacting partner, respectively, were identiﬁed. We showed that the truncation
of the disordered termini altered the folding state of the middle segment and has functional consequences
concerning its physiological function. Double truncation diminished its binding to tubulin/microtubules, conse-
quently the tubulin polymerization/microtubule bundling activities of TPPP/p25 were lost highlighting the role
of the disordered termini in its physiological function. In contrast, interaction of TPPP/p25 with α-synuclein
was not affected by the truncations and its α-synuclein aggregation promoting activity was preserved, showing
that the α-synuclein binding motif is localized within the middle segment. The distinct tubulin and α-synuclein
bindingmotives of TPPP/p25were also demonstrated at the cellular level: the double truncated TPPP/p25 did not
align along themicrotubules in contrast to the full length form, while it inducedα-synuclein aggregation. The lo-
calization of the binding motives on TPPP/p25 were established by speciﬁc ELISA experiments performed with
designed and synthesized peptides: motives at the 178–187 and 147–156 segments are involved in the binding
of tubulin and α-synuclein, respectively. The dissimilarity of these binding motives responsible for the
neomorphicmoonlighting feature of TPPP/p25 has signiﬁcant innovative impact in anti-Parkinson drug research.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The recognition that there are proteins withmore than one function
was recognized two decades ago and this characteristicwas termed ﬁrst
as gene sharing and later as moonlighting [1–3]. Moonlighting proteinsacid; BSA, bovine serum albu-
ylindole; DTE, dithioerythritol;
rier transformed infrared spec-
enase; PD, Parkinson's disease;
ction; SDS-PAGE, sodium dode-
phase peptide synthesis; TPPP/
, Research Centre for Natural
rolina út 29, H-1113, Hungary.
, olah.judit@ttk.mta.hu (J. Oláh),
im.hu (S. Szunyogh),
(F. Babos),
.hu (A. Lehotzky),
ádi).
ights reserved.perform multiple, independent functions that are not coded at gene
level, do not stem from genetic alterations (gene fusion, splice variants
or mutations), these functions are manifested at the protein level. The
functions of these moonlighting proteins can vary as a consequence of
changes in cellular localization, cell type, oligomeric state, concentra-
tions of substrates, cofactors or products [3]. Moonlighting should also
be distinguished frommultifunctionality of proteins, in which a protein
has multiple domains, each fulﬁlling a different function [2]. Recently a
subclass of the moonlighting proteins has been deﬁned as Neomorphic
Moonlighting Proteins inwhich conformational changes and/or interac-
tions with distinct partners other than at normal conditions impart a
pathological function [4]. Therefore, in the case of these moonlighting
proteins the physiological function could be converted into a patholog-
ical one [4,5].
Moonlighting is characteristic for many disordered proteins which
do not have stable,well-deﬁned 3D structures thus can adapt conforma-
tions upon binding to their partners [6,7]. Proteins with such features
are rather common in living cells. They perform essential functions
such as regulation of transcription and translation or cellular signal
transduction [6,8]. Besides that, disordered proteins also play crucial
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and Alzheimer's diseases [9,10].
Tubulin Polymerization Promoting Protein (TPPP/p25) is an intrinsi-
cally disordered protein, its extended unstructured N- and C-terminal
regions (45 and 44 aa) are straddling a middle ﬂexible segment (130
aa) [11]. It is considered as a prototype of the neomorphicmoonlighting
proteins as under physiological and pathological conditions it performs
multiple functions depending on its interacting partners. TPPP/p25 was
isolated and identiﬁed as a brain-speciﬁc protein [12] and on the basis of
its in vitro function and apparent molecular mass it was denoted TPPP/
p25 [13]. Physiologically TPPP/p25 is expressed mainly in the oligoden-
drocytes [14] of brain and plays a crucial role in their differentiation pro-
cess [15]. Its major physiological interacting partner is the tubulin/
microtubule network and itmodulatesmicrotubule dynamics and orga-
nization via its microtubule bundling activity enhancing microtubule
stability [13,16,17]. In fact, TPPP/p25 also interacts with the tubulin
deacetylase enzyme, HDAC6, and inhibits its deacetylase activity and
thus plays a role in the control of the acetylation level of microtubules
[17]. In addition, TPPP/p25 binds GTP and catalyzes its hydrolysis in a
Mg2+-dependent manner in vitro [11].
The non-physiological expression level of TPPP/p25 is coupled with
distinct central nervous system diseases such as multiple sclerosis
(altered expression in the brain and increased TPPP/p25 level in the ce-
rebrospinal ﬂuid of the patients) [18,19], oligodendrogliomas (lack of
TPPP/p25 expression) [20] or conformational diseases (co-enrichment
of TPPP/p25 and α-synuclein in inclusion bodies) [21]. The develop-
ment of the conformational diseases originates from the formation of
aberrant protein–protein interactions leading to protein aggregation
andpathological inclusion body formation. It has recently been reported
that TPPP/p25 interacts with α-synuclein and β-amyloid and promotes
their aggregation in vitro [22,23]. The involvement of TPPP/p25 in such
pathological associations leads to the etiology of PD and Multiple Sys-
tem Atrophy as we demonstrated earlier [21].
In this paper the structural and functional roles of the disordered ter-
mini of TPPP/p25 were characterized in its physiological and patholog-
ical functions, in addition, the tubulin and the α-synuclein binding
motives of TPPP/p25 involved within these functions were identiﬁed.
2. Materials and methods
2.1. Synthesis of the peptides
The peptides BF180-183 were synthesized manually by Solid
Phase Peptide Synthesis (SPPS), using Fmoc/tBu chemistry on 4-
methylbenzhydrylamine resin. The biotinylated forms were made
using biotinyl-6-amino-hexanoic acid (long chain biotin). In the case of
BF183 and BF180 a Lys was built into the C-terminus of the peptides to
conjugate the biotin derivative to its side chain (ε-amino group). The
N-terminus of the peptides was acetylated, while the C-terminus was
in amide form. The peptideswere cleaved from the resinwith anhydrous
HF in the presence of p-cresol at 0 °C. The P1–P4 peptides were synthe-
sized by automated SPPS (Syro2000; MultiSynTech GmbH, Germany),
using Fmoc/tBu strategy on 4-methylbenzhydrylamine resin with
double-coupling protocol. A Cys was built into the N-terminus of
the peptides. The N-terminus of the peptides was acetylated, while the
C-terminus was in amide form. The peptides were cleaved from
the resin with triﬂuoroacetic acid in the presence of scavengers
(ethanedithiol, tioanizol, H2O, phenol). The crude products in each case
were puriﬁed by reversed-phase chromatography and the puriﬁed com-
pounds were characterized by analytical RP-HPLC and mass spectrome-
try (PE-SCIEX API-2000 triple quadrupole instrument, Perkin-Elmer).
2.2. DNA manipulations
Prokaryotic expression vectors containing inserts for human full
length TPPP/p25 and N-terminal truncated TPPP/p25 by amino acidresidues 3–43 (TPPP/p25 delta 3–43)were prepared and puriﬁed as de-
scribed previously [17]. C-terminal truncated TPPP/p25 by residues
175–219 (TPPP/p25 delta 175–219) was ampliﬁed by polymerase
chain reaction (PCR) using forward primer 5′-AGATACACATATG GCTG
ACAAGGCTAAGC-3′, and reverse primer 5′-GGTGCTCGAGGCCCG TGAA
CTTGGTGGTGTC-3′. The double truncated TPPP/p25 corresponding to
amino acid residues 44–174 (TPPP/p25 delta 3–43/delta 175–219)
was ampliﬁed by PCR using forward primer 5′-GAGATATACATATGGC
TGCATCCCCTGAGCTC-3′ and reverse primer 5′-GGTGCTCGAGGCCCGT
GAACTTGGTGGTGTC-3′. After digestion with NdeI and XhoI restriction
enzymes inserts were ligated into pET21c vector (Novagen). Eukaryotic
expression vectors containing inserts for human full length TPPP/25
(pEGFP-TPPP/p25) were prepared as described previously [16]. The
double truncated TPPP/p25 (pEGFP-TPPP/p25 delta 3–43/delta
175–219) was ampliﬁed by PCR using the following primer pairs: 5′-
GGAATTC TATGGCTGCATCCCCTGAG-3′; 5′-ATGGATCCCTAGCCCGTGAA
CTTGGT-3′ and pEGFP-TPPP/p25 as a template. After digestion with
EcoRI and BamHI restriction enzymes inserts were ligated into pEGFP-
C1 vector (Clontech). Correct insertion of all these plasmidswas veriﬁed
by DNA sequencing.
2.3. Recombinant TPPP/p25 protein puriﬁcation
Human recombinant TPPP/p25 forms possessing a His-tag were
expressed in Escherichia coli BL21 (DE3) cells and isolated on HIS-
Select™ Cartridge (Sigma-Aldrich) as described previously [19,21].
Protein concentrations were determined from the absorbance at
280 nm using an extinction coefﬁcient of 10,095 M−1 *cm−1,
10,095 M−1 *cm−1, 5625 M−1 *cm−1 and 5625 M−1 *cm−1 for
TPPP/p25, N-terminal truncated TPPP/p25, C-terminal truncated
TPPP/p25 and double truncated TPPP/p25, respectively.
2.4. Tubulin preparation
Tubulin was prepared from bovine brain according to themethod of
Na and Timasheff [24].
2.5. α-synuclein puriﬁcation
Human recombinant α-synuclein was prepared as described previ-
ously [25]. Protein concentration was determined from the absorbance
at 280 nm using an extinction coefﬁcient of 5960 M−1 *cm−1.
2.6. Circular dichroism (CD) spectroscopy
CD measurements were performed on Jasco J-720 spectropolarime-
ter at 20 nm/min scan rate, 8 s time constant and 0.5 nm step size in
10 mM phosphate buffer, pH 7.2 at room temperature. The path length
was 0.1 cm. The protein concentrations were 4 μM for TPPP/p25 forms
and 1 μM for tubulin. The reaction mixtures were incubated for
10 min before recording the spectra. Scanning was repeated three
times, and the spectrawere averaged.Meanmolar ellipticity per residue
(Θ) in degrees square centimeter per decimolewas calculated according
to the following equation: Θ= Θm/(10*n*c*l), where Θm is the mea-
sured ellipticity in millidegrees, n is the number of amino acid residues,
c is the concentration in moles and l is the path length of the cell in
centimeters.
2.7. Fourier transformed infrared spectroscopy (FT-IR)
FT-IR spectra of the different TPPP/p25 forms were recorded with a
Bruker Equinox55 FT-IR spectrometer equipped with a liquid-
nitrogen-cooled MCT detector. The proteins (1 mM) were dissolved in
12 mM phosphate buffer containing 110 mM NaCl with D2O at pD 6.0.
Spectra were obtained by co-adding 128 scans at a spectral resolution
of 4 cm−1 in a BaF2 cell with a 50 μm spacer.
549N. Tőkési et al. / Biochimica et Biophysica Acta 1842 (2014) 547–5572.8. Limited proteolysis
TPPP/p25 forms at 1 mg/ml were digested with 0.01 mg/ml chymo-
trypsin (Sigma-Aldrich) in 50 mM tris(hydroxymethyl)aminomethane
buffer pH 8.0 containing 10 mM CaCl2 at room temperature. A control
sample did not contain protease. Aliquots were drawn from each
sample at different time points. The digestion was terminated by 1
mM 4-(2-aminoethyl) benzenesulfonyl ﬂuoride hydrochloride. The
samples were analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), separated on a Tricin-containing two-
layer-gel and stained with Coomassie Brilliant Blue R-250 containing
2-mercaptoethanol and dithioerythritol (DTE).
2.9. Fluorescence spectroscopy
Thioﬂavin T ﬂuorescence. TPPP/p25 proteins (10 μM) without and
withα-synuclein (150 μM)were incubated for 3–4 days at 37 °C in phos-
phate buffered saline (PBS) buffer. Then a 10 μl aliquotwas added to 1ml
10 μM thioﬂavin T solution in 100 mM glycine buffer, pH 8.55. The ﬂuo-
rescence spectra were measured on a FluoroMax-3 spectroﬂuorometer
(Jobin Yvon Inc.), using thermostated quartz cuvettes of 1 cm optical
path length at 37 °C. Datawere processedusingDataMax software. Scan-
ningwas repeated three times, and the spectrawere averaged, the buffer
spectrumwas subtracted in each case. Spectra were recorded at an exci-
tation wavelength (λex) of 440 nm (slit width 4 nm), emission spectra
were collected from 450 to 600 nm (slit width 4 nm).
1-anilino naphthalene-8-sulfonic acid (ANS) ﬂuorescence. Fluores-
cence spectroscopy measurements were performed in 10 mM phos-
phate buffer, pH 7.2 using a Fluoromax-3 spectroﬂuorometer (Jobin
Yvon Inc.) in a quartz cuvette of 1 cm optical path length at 25 °C. Exci-
tationwavelengthwas 380 nm,while the emissionwasmonitored from
400 to 600 nm with 2 nm slits. The data of at least three parallel mea-
surements were evaluated using DataMax software. 10 mM ANS
(Sigma-Aldrich) stock solution was freshly prepared in distilled water.
Concentrations of TPPP/p25 forms and ANS were 2.5 and 50 μM,
respectively.
2.10. Enzyme-linked immunosorbent assay (ELISA)
The plate was coated with 5 μg/ml (100 μl/well) TPPP/p25 forms in
PBS overnight at 4 °C. The wells were blocked with 1 mg/ml bovine
serum albumin (BSA) in PBS for 1 h at room temperature. Next, the
plate was incubated with serial dilutions of α-synuclein for 1 h at
room temperature in PBS. In the case of the competitive ELISA,
the plate was incubated with 500 nM α-synuclein preincubated with-
out or with the biotinylated peptides (10 and 20 μM). Then the plate
was sequentially incubated with α-synuclein antibody (1:5000,
Sigma-Aldrich) and with the peroxidase conjugated secondary IgG
(1:5000, Sigma-Aldrich). Both antibodies were in PBS buffer containing
1 mg/ml BSA, and incubated for 1 h at room temperature. Between each
incubation step the wells were washed thrice with PBS containing
0.05% Tween 20 for 10 min. The presence of antibodies was detected
using o-phenylenediamine in the concentration of 3.7 mM with 0.03%
H2O2 as substrate solution. The reaction was stopped after 10 min with
1MH2SO4, and the absorbancewas read at 490 nmwith aWallace Victor
2 multiplate reader (Perkin-Elmer). In the case of the biotinylated pep-
tides, the plate was coated with 5 μg/ml (100 μl/well) streptavidin solu-
tion in PBS overnight at 4 °C, and the wells were blocked with 1 mg/ml
BSA in PBS for 1 h at room temperature. Then the plate was incubated
with 25 μg/ml solution of the biotinylated peptides for 1 h at room
temperature in PBS. Next, the plate was incubated with serial dilutions
of α-synuclein, and the interaction was detected as described above.
In the case of P1–P4 peptides, Sulfhydryl-BIND™ (Maleimide) Mod-
iﬁed Surface plate (Corning Incorporated) was used according to
the manufacturer's instructions. Brieﬂy, the plate was coated with
5 μg/ml (100 μl/well) peptide or TPPP/p25 solution in fresh PBS buffercontaining 1 mM ethylenediamine tetraacetic acid pH 6.5 for 1 h at
room temperature. The wells were blocked with 0.2% non-fat dry milk
in PBS for 30 min at room temperature. Next, the plate was incubated
with serial dilutions of tubulin for 30 min at room temperature in PBS.
Then the plate was sequentially incubated with tubulin antibody
(1:5000, Sigma-Aldrich), andwith the corresponding peroxidase conju-
gated secondary IgG (1:5000, Sigma-Aldrich). o-phenylenediaminewas
used as substrate solution as described above.
2.11. Turbidity measurements
The assembly of tubulin (7 μM)was assessed in polymerization buff-
er (50mM2-(N-morpholino)ethanesulfonic acid buffer pH 6.6 contain-
ing 100 mM KCl, 1 mM DTE, 1 mM MgCl2 and 1 mM ethylene glycol
tetraacetic acid) at 37 °C. The tubulin polymerization into microtubules
was induced by the addition of 3 μMof the different TPPP/p25 forms. In
another set of experiments, the polymerization of 10 μM tubulin
into microtubules was induced by the addition of 20 μM paclitaxel
then subsequently 3 μM TPPP/p25 proteins were added to the solution.
The optical density wasmonitored at 350 nmby a Cary 100 spectropho-
tometer (Varian).
2.12. Pelleting experiment
Tubulin (5 μM) was incubated with the different TPPP/p25 forms
(10 μM) for 10 min at 37 °C in polymerization buffer (50 mM 2-(N-
morpholino)ethanesulfonic acid buffer pH 6.6 containing 100 mM KCl,
1 mM DTE, 1 mM MgCl2 and 1 mM ethylene glycol tetraacetic acid).
After centrifugation at 17,000 g for 15 min at 37 °C, the pellet and the
supernatant fractions were separated. The pellet fraction was washed
and resuspended in buffer. Then thepellet and the supernatant fractions
were analyzed by SDS-PAGE, separated on a Tricine-containing two-
layer-gel and stained with Coomassie Brilliant Blue R-250 containing
2-mercaptoethanol and DTE.
2.13. Cell culture and manipulation
HeLa and CHO10 cells were grown and transfected as described pre-
viously [16,17]. Formicroscopic analysis cells were grown on 12mmdi-
ameter coverslips and on 24-well plates for immunoblotting. 5 μM
MG132 (Sigma-Aldrich) was added for 4 h, where indicated. Uptake of
TPPP/p25 forms and/or α-synuclein was investigated by the addition
of 2.5/10 μg recombinant proteins into the medium freshly dissolved
in PBS buffer with or without a short preincubation.
2.14. Immunocytochemistry
HeLa and CHO10 cells were ﬁxedwith ice-coldmethanol for 10min.
After washes with PBS, samples were blocked for 30 min in PBS-0.1%
Triton X-100 containing 5% fetal calf serum. Subsequently, the
cells were stained with a monoclonal antibody against α-tubulin
(Sigma-Aldrich), a monoclonal antibody against α-synuclein (Sigma-
Aldrich) and polyclonal rat sera against human recombinant TPPP/p25
[21] followed by Alexa 488 conjugated anti-mouse antibody and Alexa
546 conjugated anti-rat antibody (Invitrogen). The samples were
washed thrice with PBS after antibody incubation. Nuclei were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI). For samples con-
taining α-synuclein, Triton X-100 was changed to 30 μM digitonin,
otherwise the protocol remained the same. Images of ﬁxed samples
were acquired on a Leica DMLS microscope. Fig. 4 was imaged on
Zeiss LSM710 confocal microscope.
2.15. Immunoblotting
The uptake of TPPP/p25 by HeLa/CHO10 cells was detected by im-
munoblotting as described previously [17] using a polyclonal rat
Fig. 1. Scheme of the different TPPP/p25 forms (A) with the SDS/PAGE images (B). (B) MM: molecular weight marker, lane 1: TPPP/p25, lane 2: N-terminal truncated TPPP/p25,
lane 3: C-terminal truncated TPPP/p25, lane 4: double truncated TPPP/p25.
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was glyceraldehyde 3-phosphate dehydrogenase (GAPDH) detected
by a monoclonal GAPDH antibody (Calbiochem).
3. Results and discussion
3.1. Structural characterization of the TPPP/p25 forms
Previously we reported that TPPP/p25 is an intrinsically disordered
protein with extended unstructured N- and C-terminal regions (45 and
44 aa) straddling a middle, ﬂexible segment (130 aa) [11]. In order to
get information whether the structural and functional properties of
TPPP/p25 are altered by the removal of the terminal segments, N- or C-Fig. 2. Structural characterization of the different TPPP/p25 forms. (A) Normalized far-UV CD s
cated TPPP/p25 (dashed line), double truncated TPPP/p25 (dotted line). The standard error
(bold line) and the double truncated (dotted line) TPPP/p25. (C) ANS ﬂuorescence spectrosco
and double truncated (dotted line) TPPP/p25. The concentration of ANS and protein was 50 μ
(n = 3–5). (D) Time-dependent limited proteolysis of the full length and the double truncate
PAGE. A representative experiment is presented. The standard error of the determinations (SEterminal truncated versions of TPPP/p25 as well as double truncated
TPPP/p25 form were produced by recombinant technique (Fig. 1).
The structural characteristics of these human recombinant TPPP/p25
formswere established by CD, FT-IR, ﬂuorescence spectroscopy and lim-
ited proteolysis. As shown in Fig. 2A, the full length TPPP/p25 displayed a
CD spectrumwith a deﬁnitiveminimumat 205nm, characteristic for dis-
ordered proteins. Absence of either the N- or the C-terminus caused
slight spectral alteration which became more pronounced in the case
of the double truncated TPPP/p25: the position of the minimum shifted
to a higher wavelength and the ratio of ellipticities measured at
222 nm and at the minimum increased (Fig. 2A).
To study whether this change can be attributed to the appearance
of the β-sheet structure, FT-IR spectroscopy was carried out in thepectra. TPPP/p25 (bold line), N-terminal truncated TPPP/p25 (solid line), C-terminal trun-
of the determinations (SEM) was ± 10% (n = 3). (B) FT-IR spectrum of the full length
py. Emission spectra of free ANS (dash-dot-dotted line), ANS with full length (bold line)
M and 2.5 μM, respectively. The standard error of the determinations (SEM) was ± 10%
d TPPP/p25 with chymotrypsin terminated at 0, 10, 20 and 40 min and analyzed by SDS-
M) was ± 10% (n = 3–4).
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bands [26,27]. We found that the FT-IR spectrum of the double truncat-
ed TPPP/p25 was not changed signiﬁcantly as compared to that of the
full length protein (Fig. 2B). The main band of the Amide I region was
at 1645 cm−1, which mainly corresponds to random conformation,
however, alpha-helix (typically around 1650–1660 cm−1) and/or
turns (1656–1671 cm−1) structures could be involved. The slight shoul-
der at 1620 cm−1 present in the spectrum of the full length TPPP/p25
may indicate the occurrence of a not signiﬁcant β-sheet structure
which is not visible in the case of the double truncated form. In addition,
minimal difference could be detected in the Amide II band (around
1565 cm−1).
In a recent work we have established the presence of “molten
globule” in the ﬂexible middle segment of TPPP/p25 by ﬂuorescence
spectroscopy [28]. ANS ﬂuorescence probe is appropriate to detect hy-
drophobic regions of proteins speciﬁcally if it is related to amolten glob-
ule state and not to globular or unfolded states [29,30]. As shown in
Fig. 2C, the truncation of the unstructured tails of TPPP/p25 resulted in
much less ﬂuorescence intensity coupled with a smaller blue shift
of the maximum of the emission spectrum. This ﬁnding could be indic-
ative for the truncation-induced conformational change in the case of
TPPP/p25.
Finally, a limited proteolysis study was performed with the full
length and the double truncated TPPP/p25 forms since it is a sensitive
tool to detect alteration in the structural integrity of proteins. The pro-
tein formswere digested with chymotrypsin, and the digests were ana-
lyzed by SDS-PAGE. Fig. 2D illustrates the results of the time-dependentFig. 3. Interaction of tubulin with the distinct TPPP/p25 forms. (A) Difference CD spectra of TPPP/
tubulin and the TPPP/p25 forms from thatmeasuredwith their mixtures. The concentration of tu
promoting potency of the TPPP/p25 forms followed by turbidimetry. The polymerization of 7 μM
microtubule bundling potency of the TPPP/p25 forms as determined by a turbidimetric assay. Tub
were added subsequently. (D) Pelleting experiment. 5 μMtubulinwas incubatedwith 10 μMof e
and the supernatant/tubulin (S) fractions were separated and analyzed by SDS-PAGE on a
line), C-terminal truncated TPPP/p25 (dashed line), double truncated TPPP/p25 (dotted lineproteolysis: the full length protein was fully degraded after 40 min,
while the double truncated TPPP/p25 displayed signiﬁcantly less vul-
nerability towards the protease, even after 40 min two stable bands
could be detected indicating the resistance of these two distinct partial-
ly digested forms against degradation. These data show that the trunca-
tion of both termini resulted in signiﬁcant structural alteration of
the middle ﬂexible segment, apparently it became more compact. Fur-
ther investigations are needed for the identiﬁcation of these stable
structures.3.2. Interaction of tubulin with the distinct TPPP/p25 forms
In order to determine whether the truncation-mediated changes in
the structure of TPPP/p25 affect its physiologically relevant function,
namely its interactionwith tubulin,we investigated the tubulin binding,
microtubule assembly promoting andmicrotubule bundling activities of
the different TPPP/p25 forms.
The tubulin binding potency of the TPPP/p25 formswas analyzed by
CD spectroscopy as we previously demonstrated by far-UV CD that the
association of TPPP/p25 with tubulin produced a characteristic differ-
ence spectrum due to the structural alterationswithin the heterologous
complex (Fig. 3A) [13]. A similar set of experiments with the truncated
forms showed that the lack of N- and/or C-terminus reduced this
effect to different extents; the double truncation virtually diminished
the formation of the difference spectrum (Figs. A.1 and 3A). Thus it
could be concluded that the disordered termini are directly or indirectlyp25 forms and tubulin. Difference ellipticity was calculated by subtracting the ellipticities of
bulin was 1 μM,while that of the TPPP/p25 formswas 4 μM. (B) The tubulin polymerization
tubulin tomicrotubuleswas induced by the addition of 3 μMof each TPPP/p25 form. (C) The
ulin (10 μM)polymerizationwas induced by paclitaxel (20 μM), andTPPP/p25 (3 μM) forms
ach TPPP/p25 form in polymerization buffer. After centrifugation, the pellet/microtubule (P)
Tris–Tricine two-layer gel. TPPP/p25 (bold line), N-terminal truncated TPPP/p25 (solid
) (A–C). The standard error of the determinations (SEM) was ± 10% (n = 3–5).
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alteration.
The functional consequences of the truncation of TPPP/p25 on its tu-
bulin polymerization promoting activity were investigated by turbidity
measurements. Typical time courses of turbidity induced by the differ-
ent TPPP/p25 forms revealed the distinct polymerization potency of
the truncated forms as compared to the full length one (Fig. 3B). It can
be unambiguously concluded that the double truncated form could
not produce tubulin polymers with length larger than 350 nm causing
turbidity. The tubulin polymerization potency of the N-terminal trun-
cated and much more that of the C-terminal truncated form was re-
duced. These results demonstrate that the disordered termini, even if
in different extent, are involved in the tubulin polymerization activity
of TPPP/p25.
Previouslywe reported that the TPPP/p25-induced tubulin polymer-
ization promoting activity is coupled with the extensive bundling of the
microtubules [13]. To test the bundling potency of the truncated forms,
two sets of experiments were performed.
In one set of experiments the effects of the full length and truncated
TPPP/p25 forms on the turbidity of paclitaxel-stabilized tubulin were
tested. Fig. 3C shows that both the single and the double truncation
of TPPP/p25 diminished its microtubule bundling activity suggesting
that the disordered termini play signiﬁcant role in the cross-linking of
microtubules.
In a second set of experiments, a pelleting experiment was
performed in which the partition of the TPPP/p25 between the pellet
(microtubules) and the supernatant (tubulin) fractionwas investigated.
As shown in Fig. 3D, both the TPPP/p25 forms and the tubulin were
partitioned between the pellet and the supernatant fractions. While in
the case of the full length TPPP/p25, the proteins were nearly equally
partitioned between the pellet and the supernatant fractions, the
amounts of both the tubulin and the truncated TPPP/p25 formswere re-
duced in the pellet fraction indicating the decreased polymerization po-
tency of the truncated TPPP/p25 forms in accordance with the turbidityFig. 4. Localization of the TPPP/p25 forms in HeLa cells. Transiently transfected cells with pEGF
nostained with α-tubulin antibody (red) and visualized by confocal microscopy. Note the co-lo
distribution of the double truncated TPPP/p25 within the cytoplasm (F). Nuclei were countersdata (Fig. 3B). The reduced polymerization potency due to the trunca-
tion was the most pronounced for the double truncated TPPP/p25.
3.3. Intracellular localization of the TPPP/p25 forms in HeLa cell
As we revealed earlier TPPP/p25 co-localizes with the microtubule
network in different cell lines expressing TPPP/p25 either exogenously
(HeLa, CHO) or endogenously (CG-4), and the protein regulates the dy-
namics and organization of themicrotubule network via itsmicrotubule
bundling activitywhich enhancesmicrotubule stability [16,17]. In order
to obtain in vivo data for the role of the disordered terminal tails
of TPPP/p25 in its microtubule-related function, HeLa cells were tran-
siently transfected with the full length or the double truncated EGFP-
TPPP/p25 and the intracellular localizations of the proteins were visual-
ized by confocal microscopy after immunostaining for α-tubulin. Fig. 4
shows that while the full length TPPP/p25 tightly co-localized with the
microtubule network in agreement with our earlier observations [16],
the double truncated form distributed homogeneously within the cyto-
plasm. The ﬁnding that the double truncated TPPP/p25 cannot associate
with the microtubule network underlines the role of the unstructured
termini in the physiological function of TPPP/p25.
3.4. Interaction of α-synuclein with the distinct TPPP/p25 forms
It has been revealed that TPPP/p25 interacts with α-synuclein [22],
and it is a potential inducer of α-synuclein ﬁbrillation [23]. In order to
identify the role of the disordered termini of TPPP/p25 in its pathologi-
cal interaction, the binding of the TPPP/p25 forms to α-synuclein and
their α-synuclein aggregation promoting activity were investigated
ﬁrst in vitro.
In an ELISA assay the afﬁnities of the double truncated and the full
length TPPP/p25 forms to α-synuclein were determined. The TPPP/
p25 forms were immobilized on ELISA plates, then α-synuclein was
added at different concentrations. Complex formation was detected byP-TPPP/p25 (A–C, green) or pEGFP-double truncated TPPP/p25 (D–F, green) were immu-
calization of TPPP/p25 along the microtubule network (C) in contrast to the homogenous
tained with DAPI (blue). Scale bar: 10 μm.
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forms (Fig. 5A) revealing that the binding motif is localized within
the middle segment as suggested by our previous Pepscan experi-
ment [22]. The binding afﬁnities of the full length and the double
truncated TPPP/p25 forms to α-synuclein evaluated by curve ﬁtting as-
suming simple hyperbolic saturation were found to be 0.59 ± 0.07 and
0.81 ± 0.09 μM, respectively.
Thioﬂavin T ﬂuorescence measurement is a suitable method to
follow the formation of amyloid-type (β-sheet rich) aggregates of
α-synuclein [31] which likely occurs in the course of pathological in-
clusion formation as demonstrated earlier [23]. Fig. 5B shows that
both the full length and the double truncated TPPP/p25 displayed
similar α-synuclein aggregation promoting potency, while auto-
aggregation of α-synuclein or the TPPP/p25 forms was not detected.
The ﬁnding that the double truncated TPPP/p25 induced α-synuclein
aggregation in concert with the ELISA data corroborates that the disor-
dered terminal tails of TPPP/p25 are probably not involved in the forma-
tion of the pathological heterocomplex.Fig. 5. The interaction of the full length and the double truncated TPPP/p25 forms with
α-synuclein. (A) ELISA experiment. The plate was coatedwith TPPP/p25 (●,▲,♦,▼) or the
double truncated form of the protein (○, Δ, ◊, ∇), then α-synuclein was added at different
concentrations. The different symbols indicate independent experiments. The normalized
ELISA data were calculated as the absorbance at a given α-synuclein concentration divided
by the absorbance at saturation. The binding afﬁnities of the full length (bold line) and the
double truncated (dashed line) TPPP/p25 forms to α-synuclein were evaluated by curve
ﬁtting assuming simple hyperbolic saturation. (B) Aggregation of α-synuclein induced by
the different TPPP/p25 forms followed by thioﬂavin T ﬂuorescence emission at 480 nm.
150 μMα-synuclein was incubated in the absence and presence of 10 μMTPPP/p25 or dou-
ble truncated TPPP/p25 in PBS buffer for 4 days at 37 °C, and the samples were analyzed by
Thioﬂavin T ﬂuorescence. TPPP/p25 or the double truncated TPPP/p25 alone was incubated
under the same conditions. The spectrum of Thioﬂavin T was subtracted from that of the
sample in each case. Error bars represent the standard error of the determinations (SEM)
(n = 3). * Signiﬁcant difference between α-synuclein and α-synuclein incubated with the
full length or the double truncated TPPP/p25 (according to the Student's t-test, p b 0.05).3.5. Colocalization of TPPP/p25 forms with α-synuclein in CHO10 cells
In order to test the role of the unstructured termini in the α-
synuclein aggregation promoting activity of TPPP/p25, an in vivo cell
model was established.
A CHO10 cell line that expresses full length TPPP/p25 ectopically fol-
lowing doxycyclin induction [17]was established as an appropriate sys-
tem since these cells could take up α-synuclein from the culture media
(Fig. 6A). This ﬁnding is in agreement with a recent report that demon-
strates the transcellular spread of secreted α-synuclein oligomers in
human H4 neuroglioma cells by exosomal transmission [32]. Here we
show that TPPP/p25 can also be taken up by both the CHO10 and the
HeLa cell lines as demonstrated by Western-blot (Fig. A.2) and the cel-
lular uptake of both the full length and the double truncated TPPP/p25
can be visualized by ﬂuorescence microscopy (Fig. 6B and C) just
as that of α-synuclein (Fig. 6A). The intracellular appearance of
α-synuclein or the double truncated TPPP/p25, but not the full length
TPPP/p25 resulted in the formation of aggregates in a few cases
(Fig. 6A and C vs B).
The α-synuclein aggregation promoting activity of the TPPP/p25
forms was characterized in CHO10 cells with and without the expres-
sion of the full length TPPP/p25. As shown in Fig. 7, co-aggregation of
α-synuclein with either the full length or the double truncated TPPP/
p25 forms can be visualized in non-induced CHO10 cells where all
these proteins were taken up by the cells from the medium after their
premixing (Fig. 7 lane 3 and 4, respectively). The added double truncat-
ed TPPP/p25 apparently displayed higher aggregation promoting activ-
ity as compared to the full length one, probably due to the fact that it is
unable to bind to the microtubule network (cf. Fig. 4) therefore its free
intracellular level is higher resulting in more pronounced α-synuclein
aggregation promoting activity. The expression of the full length
TPPP/p25 after doxycyclin induction only slightly contributed
to α-synuclein aggregate formation (Fig. 7, lane 1 vs lane 3). The
expressed full length TPPP/p25 rather co-localized with the microtu-
bule network than with α-synuclein (Fig. 7 lane 1 and 2, Fig. A.3) as
its binding afﬁnity to tubulin is higher than toα-synuclein [22]. In con-
trast,when double truncated TPPP/p25was added to themedium in ad-
dition to the TPPP/p25 expression, the aggregates increased in number
and size (Fig. 7 lane 2 vs lane 1), which conﬁrms the more pronounced
α-synuclein aggregation promoting potency of the double truncated
TPPP/p25 and strengthens our suggestion that it is because of its higher
free intracellular level due to its inability to bind to microtubules. Nev-
ertheless, these ﬁndings provide evidence for the intracellular associa-
tion of both TPPP/p25 forms with α-synuclein and support that the
disordered termini do not take part in the formation of pathological
aggregates.
The extracellular transmission of these disordered hallmark proteins
seems to have pathological signiﬁcance and may explain how the co-
enrichment of α-synuclein and TPPP/p25 could be evolved in the case
of PD and Multiple System Atrophy in neurons and oligodendroglia
cells, respectively, though under physiological conditions these cells
do not express these two proteins simultaneously. Indeed, the presence
of both α-synuclein and TPPP/p25 was detected in the cerebrospinal
ﬂuid of human patients previously [19,33,34].3.6. Validation of the tubulin and α-synuclein binding motives of TPPP/p25
To validate the binding motives within the C-terminus (44 aa) and
the middle ﬂexible segment (130 aa) of TPPP/p25 that are predomi-
nantly involved in its heteroassociation with tubulin and α-synuclein,
respectively, special ELISA experiments were performed with synthe-
sized TPPP/p25 peptides.
For the identiﬁcation of the tubulin binding motif of TPPP/p25, pep-
tides were designed and synthesized according to data obtained with
the truncated forms as compared to the full length TPPP/p25 and
Fig. 6. Cellular uptake ofα-synuclein or the TPPP/p25 forms as detected by immunoﬂuorescencemicroscopy. Non-induced CHO10 cells took up human recombinantα-synuclein (A, red)
or the TPPP/p25 forms (B and C, red) from the cell culturemedia as visualized by immunostaining forα-synuclein or TPPP/p25, respectively. The TPPP/p25 formswere stained by the same
antibody [21]. Nuclei were counterstained with DAPI (blue). Scale bar: 2.5 μm.
Fig. 7. Intracellular localization of the TPPP/p25 forms and α-synuclein in CHO10 cells as detected by immunoﬂuorescence microscopy. CHO10 cells with (lanes 1–2) and without
(lanes 3–4) full length TPPP/p25 expression took up full length (lanes 1 and 3, red) or double truncated (lanes 2 and 4, red) TPPP/p25 andα-synuclein (lanes 1–4, green) from themedium
after premixing as visualized by immunostaining for TPPP/p25 andα-synuclein, respectively. Note that either the expressed (lanes 1 and 2) or the added full length TPPP/p25 (arrowhead
at lane 3) was rather colocalized with the microtubule network than with α-synuclein. The double truncated TPPP/p25 and α-synuclein were co-enriched in cytoplasmic aggregates
(lanes 2 and 4) whichwere more pronounced both in number and size than the aggregates induced by full length TPPP/p25 expression (lane 1) or uptake (lane 3). Nuclei were counter-
stained with DAPI (blue). Scale bar: 2.5 μm.
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tubulin binding site of tau [35]:
tubulin binding motif of tau: 315VYKPVDLSKVTSKCGSLGNIHHK
PGGGQ341;
C-terminal tail of TPPP/p25: 163VSRLTDTTKFT - - - GSHKERFD
PSGKGK187.
Accordingly, the following overlapping decapeptides were synthe-
sized with a Cys residue that rendered possible their direct immobiliza-
tion to an ELISA plate via their SH groups:
P1 C163VSRLTDTTKF172
P2 C168DTTKFTGSHK177
P3 C173TGSHKERFDP182
P4 C178ERFDPSGKGK187
Tubulin at different concentrations was added to the immobilized
peptides; the peptide-bound tubulinwas quantiﬁedwith a tubulin anti-
body as described in Section 2.
The P4 peptide (178–187 aa) bound to tubulin with comparable af-
ﬁnity as TPPP/p25 (Kd = 0.135 ± 0.041 and 0.180 ± 0.030 μM for
TPPP/p25 and P4 peptide, respectively), while the three other peptides
displayed lower afﬁnity (Fig. 8). Accordingly, the 178ERFDPSGKGK187
segment of the C-terminal tail is the key binding motif on TPPP/p25 re-
sponsible for tubulin binding. Nevertheless, this issue does not exclude
the involvement of other parts such as the N-terminal tail in the func-
tion of TPPP/p25 as noticed in the case of the turbidity measurements
(cf. Fig. 3).
To reinforce the localization of the α-synuclein binding motif in a
speciﬁc segment of the middle region of TPPP/p25 suggested by the
Pepscan data, 147KAPIISGVTKAISSPTVSRL166 [22], ELISA experiments
were performed with biotinylated decapeptides. The peptides were
synthetized to cover the potential α-synuclein binding segment. The
decapeptides with biotinylated tag rendered it possible to test the bind-
ing potency of the α-synuclein directly to the peptides immobilized on
a streptavidin-covered plate. To test whether the biotinylation of the
peptides at one of their termini affects the interactions, modiﬁcation
of one of the peptides at N- or C-terminus was alternatively performed
as shown below:
BF180: C-biotinylated: Ac-142RLIEGKAPII151K-NH2
BF181: N-biotinylated: H-142RLIEGKAPII151-NH2
BF182: C-biotinylated: Ac-147KAPIISGVTK156-NH2
BF183: C-biotinylated: Ac-157AISSPTVSRL166K -NH2
There is no signiﬁcant difference in the binding afﬁnity of the
α-synuclein to the immobilized peptides as revealed by a speciﬁcFig. 8. The interaction of TPPP/p25 and the decapeptides with tubulin followed by ELISA.
The plate was coated with the P1–P4 peptides or TPPP/p25 via their SH groups, then it
was incubated with tubulin at different concentrations. TPPP/p25 (●), P1 (Δ), P2 (○),
P3 (◊) and P4 (▲).α-synuclein antibody (Fig. 9A). The apparent afﬁnity constants (Kd) ob-
tained by ﬁtting the experimental points with a simple hyperbolic satu-
ration curve were 2.91 ± 0.69, 3.60 ± 0.57, 4.15 ± 0.24 and 4.01 ±
0.18 μM for the BF180, BF181, BF182 and BF183 peptides, respectively;
which are signiﬁcantly higher than that determined for the double trun-
cated (0.81±0.09 μM)and for the full length (0.59±0.07 μM)TPPP/p25
(cf. Fig. 5A). The α-synuclein binding is apparently independent of the
nature of the decapeptides selected aswell as the position of the biotinyl-
ation label. Consequently one can conclude that the binding is indepen-
dent of the position of the biotinylation, but cannot exclude its role in the
binding.
Another, competitive ELISA experiment was carried out with the bi-
otinylated peptides, however, they were premixed with α-synuclein in
solution then added to the full length or double truncated TPPP/p25
forms immobilized on ELISA plates. The inhibitory effect of the peptides
on the binding of α-synuclein to TPPP/p25 forms was detected by a
speciﬁc α-synuclein antibody. In the experiment presented in Fig. 9B,
α-synuclein was added at constant concentration which corresponded
roughly to the half saturation value (cf. Fig. 5A), and the peptides
were preincubated with α-synuclein at 10 and 20 μM concentrations.
The results showed that i) there was a single peptide, BF182, which
inhibited the heteroassociation of the α-synuclein with TPPP/p25;
ii) the extent of the inhibition was similar in the case of the full lengthFig. 9. The interaction of decapeptides with α-synuclein followed by ELISA and the effect
of biotinylated peptides on TPPP/p25 – α-synuclein interaction. (A) The plate was coated
with streptavidin, then the biotinylated peptides were added to the plate. Next it was
incubated with α-synuclein at different concentrations. BF180 (●, solid line), BF181
(○, dashed line), BF182 (▲, dotted line) and BF183 (Δ, dash-dot-dotted line). (B) The
plate was coated with the full length (white column) or the double truncated (black col-
umn) TPPP/p25 form. Then 500 nM α-synuclein preincubated with the biotinylated pep-
tides BF180–183 (10 and 20 μM) was added to the plate. The interaction was detected by
an α-synuclein antibody. Error bars represent the standard error of the determinations
(SEM) (n = 3).
Fig. 10. Scheme of the tubulin andα-synuclein bindingmotives of TPPP/p25 as validated by different TPPP/p25 peptides. Localization of the different TPPP/p25 peptides in the sequence of
TPPP/p25 and the amino acid sequence of the potential binding site of tubulin (green) and α-synuclein (blue) are shown in red frames.
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was concentration-dependent; iv) the BF180, BF181 and BF183
peptides were virtually ineffective concerning their inhibitory effects
on the heteroassociation independently of the position of the biotinyl-
ation. These data seem to contradict the direct binding data where the
α-synuclein displayed similar afﬁnity to each biotinylated TPPP/p25
peptide (Kd ~ 4 μM), in addition, this afﬁnity was lower as determined
for the full length/double truncated protein (Kd = 0.59 μM/0.81 μM).
A plausible way to interpret these ELISA data is that the disordered
α-synuclein may have another binding segment interacting with the
biotinylated TPPP/p25 peptides, but the segment is out of the contact
surface of the TPPP/p25-α-synuclein pathological complex.
The ﬁndings with the peptides and truncated TPPP/p25 forms
suggest that the amino acids and/or short peptides within the middle
segment of TPPP/p25 could generate a speciﬁc structure such as a
foldamer, for the α-synuclein binding to form the pathologically rele-
vant heteroassociation leading to aggregation.4. Conclusions
In conclusion, TPPP/p25 is a protein with a neomorphic moonlight-
ing feature that is related to its disordered structurewhich permitsmul-
tiple interactions with distinct proteins forming physiological or
pathological complexes. In this paper the structural and functional fea-
tures of the disorderedN- andC-terminal tails of TPPP/p25were charac-
terized. Our data revealed the key role of the C-terminus and the fact
that the N-terminus is also involved, even if to a much less extent, in
its physiological function related to the modulation of the dynamics
and organization of the microtubule network. In contrast, the α-
synuclein binding and aggregation promoting activity of TPPP/p25 is
virtually not inﬂuenced by the truncation of the terminal tails.
Experiments with designed and synthesized TPPP/p25 peptides
rendered it possible to validate the binding motives for tubulin and α-
synuclein (Fig. 10). The ELISA experiments with decapeptides covering
the potential tubulin and α-synuclein binding segments localized these
bindingmotives on the C-terminal tail (178ERFDPSGKGK187) andwithin
the middle region (147KAPIISGVTK156) of TPPP/p25, respectively. The
results obtained with the overlapping decapeptides may allow one to
further reduce the binding motives to ﬁve-amino-acid segments
which are substantial for the formation and maintenance of physiolog-
ical and pathological heterocomplexes. The distinct localization of these
binding motives in the disordered TPPP/p25 assigns its neomorphicmoonlighting functions and has innovative potential in the develop-
ment of anti-synucleinopathy drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.01.009.
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